908 Devices brings defense-focused chemical analysis tools to FIDAE exhibition
908 Devices is currently showcasing its chemical analysis tools designed for defense and security applications at the FIDAE exhibition in Santiago, Chile, in partnership with Aerotech. The company has a history of presenting chemical identification devices at key events and recently launched its MX908 device to enhance the detection of novel psychoactive substances. These efforts underscore 908 Devices' commitment to real-time detection solutions for critical security and defense needs.
908 Devices urges shift from basic detection to precise identification in analytical tools
908 Devices is advocating for a paradigm shift in analytical tools, moving beyond basic detection to precise identification and quantification of substances. The company emphasizes that modern environments necessitate a higher standard for analytical capabilities. In line with this, 908 Devices has introduced new chemical identification devices and a rapid hazmat detection demo to meet advanced mission needs.
908 Devices Enhances MX908 Usability and Adds New Drug Targets
908 Devices has announced new enhancements for its handheld MX908 mass spectrometry device, improving its usability for trace chemical identification. The updates include a new TIC Hunter mode for hazardous vapor detection, replacing the broader Hazard Survey mode, and the addition of five new priority drug targets, such as medetomidine and several synthetic cathinones, cannabinoids, and benzodiazepines. These enhancements provide first responders with more focused tools and expanded drug detection capabilities to address evolving illicit drug landscapes.
908 Devices deploys next generation MX908 for real time detection of novel psychoactive substances
908 Devices has launched its MX908 device to enable law enforcement and first responders to rapidly detect novel psychoactive substances, synthetic drugs, and opioids. This new tool addresses the challenge of traditional detection methods being outpaced by the emergence of new drug threats. The company has also previously showcased other chemical identification and hazmat detection technologies, underscoring its focus on mission-ready detection solutions.
908 Devices Inc. (MASS) reports Q4 loss, tops revenue estimates
908 Devices Inc. (MASS) reported a narrower-than-expected loss in the fourth quarter, with a loss per share of 57 cents compared to analyst estimates of 61 cents. The company also surpassed revenue expectations, bringing in $12.3 million against a forecasted $11.5 million. Despite the revenue beat, the company's net loss increased year-over-year.
908 Devices unveils MX908 detection at KEYS Conference in Concord
908 Devices is showcasing its MX908 detection technology at the KEYS Conference in Concord, California. The device is designed for rapid identification of invisible trace residues on inmate mail and jail surfaces, enhancing security in correctional facilities. This presentation builds on 908 Devices' previous innovations in chemical detection, including technologies for CBRN missions and rapid hazmat detection.
908 Devices to Present at the Sidoti Small Cap Conference
908 Devices Inc. will present at the Sidoti Small Cap Conference on Wednesday, March 18, 2026, featuring CEO Kevin J. Knopp and CFO Joe Griffith. The company, which specializes in handheld chemical analysis tools for health, safety, and defense, will host investor meetings and provide a live audio webcast of their presentation. An archived version will be available on their investor website.
908 Devices to Present at the Sidoti Small Cap Conference
908 Devices Inc. (Nasdaq: MASS) announced that its CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings virtually at the Sidoti Small Cap Conference on Wednesday, March 18, 2026, at 1:45 p.m. Eastern Time. A live audio webcast will be available, and an archived webcast will be posted on the company's investor relations website. The company specializes in handheld chemical analysis tools for health, safety, and defense tech applications.
908 Devices to Present at the Sidoti Small Cap Conference
908 Devices Inc. (Nasdaq: MASS) announced that its CEO and Co-founder, Kevin J. Knopp, and CFO, Joe Griffith, will present and host investor meetings virtually at the Sidoti Small Cap Conference on Wednesday, March 18, 2026, starting at 1:45 p.m. Eastern Time. A live audio webcast will be available, and an archived version will be accessible on the company's investor relations website. The company specializes in handheld chemical analysis tools for vital health, safety, and defense applications.
Handheld chemical tools maker 908 Devices to meet investors online
908 Devices Inc. (Nasdaq: MASS), a company specializing in handheld chemical analysis tools, announced that its CEO and CFO will present and host investor meetings at the Sidoti Small Cap Conference on March 18, 2026. The presentation is scheduled for 1:45 p.m. ET and will be accessible via live audio webcast. The company focuses on developing devices for vital health, safety, and defense tech applications, including addressing drug crises, toxic exposures, and security threats.
MASS - 908 Devices Inc. Latest Stock News & Market Updates
This page provides the latest stock news and market updates for 908 Devices Inc. (NASDAQ: MASS), a company specializing in handheld chemical analysis devices for health, safety, and defense applications. The news covers financial results, product developments, adoption by government and defense organizations, and corporate governance. Key highlights include strong 2020 financial results, a $25 million purchase order from the U.S. Army, and the company's IPO in December 2020.
[EFFECT] 908 Devices Inc. SEC Filing
908 Devices Inc. (NASDAQ: MASS) announced the effectiveness of an S-3 shelf registration statement by the SEC. The filing reports that the statement became effective on March 13, 2026, at 4:01 P.M. The company's market capitalization is $217.52 million.
908 Devices’ Smaller-Reporting Status May Curb Transparency, Weigh on Investor Appeal and Volatility
908 Devices Inc. (MASS) faces potential challenges due to its status as a smaller reporting company and non-accelerated filer. This status allows for scaled-back SEC disclosure and avoids auditor attestation, which could reduce transparency and control assurance. Consequently, this might make the shares less attractive to some investors, potentially leading to lower trading liquidity and increased stock price volatility.
908 Devices (NASDAQ:MASS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded 908 Devices (NASDAQ:MASS) from a "hold" to a "buy" rating, although Weiss Ratings reissued a "sell." Despite a mixed analyst outlook, 908 Devices exceeded quarterly earnings and revenue estimates. Institutional investors, notably First Light Asset Management, have significantly increased their stakes in the company, while the CFO sold a portion of his shares.
908 Devices (NASDAQ: MASS) files $100M shelf registration to raise capital
908 Devices Inc. (NASDAQ: MASS) has filed a $100 million shelf registration (Form S-3) with the SEC, allowing it to raise capital by intermittently offering various securities such as common stock, preferred stock, debt securities, warrants, and units. This filing establishes a mechanism for future fundraising without committing to an immediate issuance. The common stock was trading at $6.75 per share on March 5, 2026, and proceeds are intended for general corporate purposes and working capital.
908 Devices 2025 10-K: Revenue $56.2M, EPS $0.54
908 Devices reported 2025 revenue of $56.2 million and GAAP net income per share of $0.54, marking a significant return to profitability. This was largely driven by a $55.9 million gain from the sale of its Desktop Portfolio. The company also saw an 18% increase in revenue year-over-year, alongside strategic acquisitions, product launches, workforce reductions, and a headquarters move.
908 Devices (MASS) legal officer reports option and RSU awards
908 Devices Inc. filed an initial Form 3 for Chief Legal and Administrative Officer Mark S. Levine, reporting his existing equity awards. Levine holds stock options covering 130,468 shares and 98,242 restricted stock units (RSUs). Both the options and RSUs have staggered vesting schedules contingent on his continued service, with vesting beginning in 2026 and 2027 respectively.
908 Devices (MASS) SVP exercises options and sells common shares
Kevin J. McCallion, SVP of Products and Production at 908 Devices Inc. (MASS), reported exercising options for 7 shares at $1.05 per share and subsequently selling 7 common shares at $7.00 per share on March 2, 2026. These transactions were conducted under a Rule 10b5-1 trading plan. Following these trades, McCallion holds 26,686 option shares and 44,925 common shares.
908 Devices Inc. $MASS Shares Bought by First Eagle Investment Management LLC
First Eagle Investment Management LLC significantly increased its stake in 908 Devices Inc. (NASDAQ:MASS) by 125.9% in the third quarter, now owning 603,962 shares worth approximately $5.29 million. This increase follows 908 Devices beating Q4 earnings expectations and providing a positive FY-2026 revenue outlook, which contributed to a 6.6% share price gain. Despite this, the company remains unprofitable on a GAAP basis, and analyst sentiment is mixed with a "Hold" consensus rating.
908 Devices (NASDAQ: MASS) SVP details stock options and RSUs
Kevin J. McCallion, SVP of Products and Production at 908 Devices Inc. (NASDAQ: MASS), filed an initial ownership report detailing his equity holdings. The filing, a Form 3, indicates he holds 44,925 shares of common stock directly, along with significant stock option awards and restricted stock units (RSUs). These derivative securities have multi-year vesting schedules, generally conditioned on his continued service through various dates extending to February 1, 2027.
908 Devices (MASS) SVP McCallion sells shares under 10b5-1 plan
Kevin J. McCallion, Senior Vice President of Products and Production at 908 Devices Inc. (MASS), sold 7 shares of common stock at $7.00 per share on March 2, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. After the sale, McCallion directly holds 44,918 common shares.
Stifel reiterates Buy rating on 908 Devices stock at $8 target
Stifel maintained its Buy rating and $8.00 price target on 908 Devices Inc. (NASDAQ:MASS), noting the company's strong performance, including a 63% gain over the past year and solid operational execution. Despite gross margins being slightly below expectations and an anticipated sales decline this year, Stifel forecasts full-year EBITDA positivity by 2027. Recent Q4 2025 results also showed significant outperformance in EPS and revenue, reinforcing investor confidence.
908 Devices Inc. (NASDAQ:MASS) Q4 2025 Earnings Call Transcript
908 Devices Inc. reported strong Q4 and full-year 2025 financial results, exceeding earnings expectations with $17.4 million in Q4 revenue (21% YoY growth) and achieving positive adjusted EBITDA of $700,000. The company's performance was driven by demand for its Explorer and new Viper devices, international expansion, and strategic operational efficiencies. For 2026, 908 Devices projects revenue between $64.5 million and $67.5 million, emphasizing continued growth in handheld products, OEM partnerships, and the AVCAD program, while aiming to halve its adjusted EBITDA loss.
908 Devices (MASS) Q3 Losses Deepen Skepticism Around Bullish Margin Recovery Narratives
908 Devices (MASS) reported Q3 revenue of US$14.0 million and an EPS loss of US$0.41, continuing a trend of heavy losses despite rising revenues. The company's trailing twelve-month revenue was US$65.0 million with a net loss of US$72.7 million. While bulls hope for recurring revenue from healthcare and law enforcement and margin improvements through technology, current figures show persistent unprofitability and a five-year earnings decline.
908 Devices Inc (MASS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Partnerships Propel Future Prospects
908 Devices Inc (MASS) reported strong Q4 2025 results with a 21% year-over-year revenue growth and positive adjusted EBITDA, driven by the successful launch of the Viper device and increased international sales. Despite a net loss for the full year, the company is optimistic about future growth through strategic partnerships, the upcoming NextGen MX 908 platform, and leveraging integrations with unmanned vehicles. Geopolitical factors are also boosting demand for their products, and the company expects continued growth from the FTIR replacement cycle.
908 Devices Inc. (MASS) Posts Q4 Loss but Exceeds Revenue Expectations
908 Devices Inc. (MASS) reported a smaller-than-expected quarterly loss of $0.05 per share, surpassing the anticipated loss of $0.06 and significantly improving from the prior year's $0.32 loss. The company also exceeded revenue expectations, generating $17.38 million against consensus projections, though this was slightly lower than the previous year's $18.82 million. Despite mixed estimate revisions, the stock holds a Zacks Rank #3 (Hold), with shares climbing approximately 25.9% year-to-date.
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results
908 Devices Inc. announced its fourth quarter and full year 2025 financial results, showing significant revenue growth and positive Adjusted EBITDA in Q4 2025. The company reported a 21% increase in Q4 revenue to $17.4 million and an 18% increase in full-year revenue to $56.2 million. Strategic divestment of its bioprocessing portfolio in March 2025 contributed to strengthened operations and expanded margins, with a positive outlook for 2026 revenues.
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS) announced strong financial results for the fourth quarter and full year 2025, with Q4 revenue up 21% and full-year revenue increasing 18% to $56.2 million. The company achieved positive Adjusted EBITDA in Q4 2025 and ended the year with $113.0 million in cash. Looking ahead, 908 Devices projects 2026 revenues to be between $64.5 million and $67.5 million, reflecting 15% to 20% growth.
An Overview of 908 Devices's Earnings
908 Devices (NASDAQ: MASS) is set to release its quarterly earnings, with analysts anticipating an EPS of $-0.06. The company's stock has seen a 77.84% increase over the last year, despite past earnings misses leading to share price drops. The article also provides an overview of 908 Devices's financial health, noting its impressive net margin but challenges in revenue growth and returns on equity and assets.
908 Devices unveils layered detection tech aiding customs in intercepting hidden drugs and mislabeled chemicals
908 Devices has introduced advanced layered detection technology to assist customs officials in identifying concealed drugs and verifying mislabeled chemicals at borders. This innovation aims to enhance interdiction capabilities without hindering legitimate trade flows. The company detailed how this technology improves security and operational speed in a recent blog post.
908 Devices (MASS) Projected to Post Earnings on Tuesday
908 Devices (NASDAQ:MASS) is anticipated to report its Q4 2025 earnings before market open on Tuesday, March 3rd, with analysts forecasting a loss of ($0.06) per share and revenue of $16.19 million. The company's stock trades at $6.49, has a market capitalization of $234.87 million, and a "Hold" consensus rating with a $12.00 price target from Wall Street analysts. Insider activity shows CFO Joseph H. Iv Griffith recently sold 23,175 shares, reducing his stake by over 14%, while institutions hold approximately 88% of the stock.
908 Devices to Participate in Investor Conferences in March
908 Devices Inc. (Nasdaq: MASS) announced its participation in two investor conferences in March. The company will hold a fireside chat at the TD Cowen 46th Annual Healthcare Conference on March 4 and another at the Leerink Global Healthcare Conference on March 9. Live and archived webcasts of these sessions will be available on the company's investor relations website.
MASS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of 908 Devices Inc. (MASS), detailing its income statement, balance sheet, cash flow, and key financial ratios for five years of annual and quarterly data. The company exhibits strong revenue growth and liquidity but struggles with profitability, reflected in negative operating and net margins, and has a low Piotroski F-Score indicating weak financial health. Despite low leverage, its earnings quality is considered low due to reliance on accounting accruals rather than cash generation.
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results, which will be accessible on its investor relations website. 908 Devices specializes in handheld chemical analysis tools for health, safety, and defense applications.
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will report its financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Following the release, company management will host a conference call webcast at 8:30 a.m. Eastern Time. The webcast will be accessible through the "Investors" section of the company's website and will be archived for replay.
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will release its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 3, 2026. Management will host a webcast conference call at 8:30 a.m. Eastern Time, accessible via the "Investors" section of their website. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
908 Devices accelerates chemical identification with MX908 for safer handling
908 Devices has launched its new MX908 device, designed to improve chemical identification for faster and more secure decision-making. This product provides clear chemical analysis, which is crucial for investigations and legal prosecutions. The company highlights the MX908's reliability in results, aligning with its commitment to advanced corrections technology and trace detection for enhanced facility safety.
908 Devices Reports Strong Growth and Technological Advancements
908 Devices delivered a strong financial performance in 2025, with revenue reaching $56.0 million, exceeding projections. The company also rolled out significant software upgrades for its MX908 mass spectrometer, enhancing its chemical analysis capabilities for first responders. The market for portable mass spectrometry is expected to grow significantly, with 908 Devices well-positioned to capitalize on this trend.
908 Devices Enhances MX908 Usability and Adds New Drug Targets
908 Devices Inc. has released new enhancements for its MX908 mass spectrometry device, improving usability and expanding its drug detection capabilities. The updates include a new TIC (toxic industrial chemical) Hunter mission mode for hazardous vapor sampling and the addition of five priority drug targets, such as medetomidine ("rhino tranq"), N-isopropyl butylone, ADB-PINACA, MDMB-BINACA, and Bromazolam. These enhancements aim to provide first responders with faster and more reliable chemical identification for critical decision-making in evolving threat landscapes.
Griffith, 908 Devices CFO, sells $143k in MASS stock By Investing.com
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares for approximately $143,221 on February 2, 2026. This transaction occurred shortly after he acquired 70,035 shares through Restricted Stock Units on February 1, 2026, and despite the stock showing a significant 171.73% return over the past year. InvestingPro analysis suggests the stock is undervalued, and the company maintains a strong financial position with more cash than debt.
908 Devices (NASDAQ:MASS) CFO Sells $143,221.50 in Stock
908 Devices Inc. (NASDAQ:MASS) CFO Joseph Iv Griffith sold 23,175 shares of the company's stock for a total of $143,221.50, reducing his position by 14.21%. The shares traded up 4% to $6.44, with the company having a market cap of $233.06 million and a negative P/E ratio. The company missed recent quarterly EPS expectations, and analysts currently have a "Hold" rating with an average price target of $12.00, while Weiss Ratings reiterated a "sell" rating.
Griffith, 908 Devices CFO, sells $143k in MASS stock
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares worth approximately $143,221 on February 2, 2026, after the stock experienced a significant annual return. Despite this sale, Griffith also acquired over 70,000 shares through Restricted Stock Units and Stock Options, and the company reported strong preliminary revenue for 2025 while maintaining a healthy financial position. InvestingPro analysis suggests the stock may be undervalued, offering further insights for investors.
Griffith, 908 Devices CFO, sells $143k in MASS stock
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares for approximately $143,221 on February 2, 2026, with the stock trading near $6.44 and having returned 171.73% over the past year. He also acquired 70,035 shares through restricted stock units and further stock options and RSUs on February 1, 2026. The company shows strong momentum with a 22.67% year-to-date gain, holds more cash than debt, and reported preliminary unaudited revenue of $56 million for 2025.
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
908 Devices Inc. announced strong preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company expects full-year revenue to be approximately $56.0 million, representing a 17% year-over-year growth, and achieved its goal of positive Adjusted EBITDA in the fourth quarter. These results, driven by performance in the U.S. and international markets, position the company well for future growth in chemical detection.
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
908 Devices Inc. (NASDAQ:MASS) recently saw its share price rebound by 29% in 30 days, contributing to a 152% annual gain. Despite this surge, its high price-to-sales (P/S) ratio of 3.9x is concerning given that the company's revenue is forecast to decrease by 3.5% next year, while the broader Electronic industry is expected to grow by 20%. Investors are cautioned that the elevated P/S ratio and anticipated revenue decline suggest the current stock prices may not be sustainable.
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
908 Devices Inc. (NASDAQ:MASS) recently experienced a 29% stock price rebound, contributing to a 152% annual gain. However, the company's Price-to-Sales (P/S) ratio of 3.9x is considered high compared to the industry average of 2.8x. Analysts project a 3.5% revenue decrease for the coming year, while the broader electronic industry is expected to grow by 20%, raising concerns about the sustainability of the current stock valuation despite past revenue growth.
908 Devices Q4 sales jump 20% as it turns Adjusted EBITDA positive
908 Devices Inc. announced strong preliminary unaudited financial results for Q4 and full year 2025, with Q4 revenue increasing by 20% to $17.2 million and full year revenue reaching approximately $56.0 million, a 17% growth. The company achieved its goal of positive Adjusted EBITDA in the fourth quarter. This performance was attributed to robust sales in U.S. state and local channels, international adoption of VipIR, and sales to federal and defense customers, positioning the company for future growth.
908 Devices reports preliminary Q4 revenue $17.2M, consensus $15.92M
908 Devices reported preliminary Q4 revenue of $17.2M, surpassing the consensus estimate of $15.92M. This strong performance was attributed to growth in the U.S. state and local channels, international adoption of VipIR, and sales to federal and defense customers. CEO Kevin Knopp highlighted the company's transformation to a "stronger, simpler, and more profitable financial model" focusing on frontline chemical detection, achieving positive Adjusted EBITDA in Q4, and benefiting from macro trends like increased funding for the fentanyl crisis and global defense budgets.
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
908 Devices Inc. (Nasdaq: MASS) announced strong preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company expects full-year 2025 revenue of approximately $56 million, representing a 17% year-over-year growth, and achieved its goal of positive Adjusted EBITDA in the fourth quarter. This performance was attributed to strong U.S. state and local channel sales, international VipIR adoption, and sales to federal and defense customers, positioning the company for future growth.
908 Devices Launches a 3-in-1 Handheld Analyzer
908 Devices has launched VipIR, a 3-in-1 handheld analyzer designed for rapid and reliable field-based chemical identification of unknown bulk solids and liquids, including hazardous compounds, explosives, and drugs. Utilizing patented Smart Spectral Processing (SSP), VipIR dynamically combines data from FTIR and Raman spectroscopy from a single sample to provide accurate chemical identification. This device aims to streamline processes and remove uncertainty for hazardous response teams and border staff.
